Edwards Lifesciences stock holds near $90 after earnings
Published on 08/28/2026 at 13:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edwards Lifesciences stock (US28176E1082) held near $90 after the company reported $1.74 billion in revenue and $0.78 in earnings per share for the quarter ended July 23, 2026. The same update showed revenue growth of 13.6% from a year earlier and EPS $0.04 above consensus.
Earnings stay central
Market data showed Edwards Lifesciences at $89.92 on August 27, 2026, with a market cap of $51.888 billion and a daily decline of 0.95%. A separate market snapshot put the stock at $89.97 at the open on August 28, 2026, while the 52-week move was listed at 11.2% in one overview.
The combination of a $51.8 billion valuation and a 51.71 P/E ratio keeps the stock in a premium range for a medical device name. That makes the next guidepost important: Q3 2026 EPS guidance of $0.710 to $0.770 and full-year 2026 EPS guidance of $2.950 to $3.050.
Guidance frames the trade
Consensus expectations in one snapshot pointed to about $3.00 in full-year EPS for 2026, which sits inside management's range. The July quarter also included a 15.43% net margin and a 15.68% return on equity, underscoring a profitable base as growth reaccelerates.
A separate analyst-style overview said FY2025 revenue was $6.1 billion, operating income was $1.3 billion, and diluted EPS was $1.83. Those figures serve as historical context, while the current operating debate stays centered on whether the July quarter's 13.6% revenue growth can carry through the rest of 2026.
Product mix matters
Edwards Lifesciences sells transcatheter heart valves, surgical heart valve repair products, and hemodynamic monitoring systems. Those categories remain the commercial engine behind the company's revenue base and the earnings leverage visible in the latest quarter.
Shares and valuation
Edwards Lifesciences stock last closed at $89.92 on August 27, 2026, and a separate quote page put the shares at $89.50 with a last update at 19:54 on August 27, 2026. At that level, the stock traded close to the $51.8 billion market-cap mark and above the company's FY2025 profit base.
Fact box
Company: Edwards Lifesciences Corporation
ISIN: US28176E1082
Ticker: EW
Exchange: NYSE
Price (as of August 27, 2026): $89.92 USD
Market cap: $51.888 billion
Sector / Industry: Health Care / Medical Devices
Index membership: S&P 500
